Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms.
Murphy T, Mason JM, Leber B, Bray MR, Chan SM, Gupta V, Khalaf D, Maze D, McNamara CJ, Schimmer AD, Schuh AC, Sibai H, Trus M, Valiquette D, Martin K, Nguyen L, Li X, Mak TW, Minden MD, Yee KWL. Murphy T, et al. Among authors: leber b. Leukemia. 2024 Mar;38(3):502-512. doi: 10.1038/s41375-023-02110-9. Epub 2023 Dec 19. Leukemia. 2024. PMID: 38114624
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry.
Buckstein R, Chodirker L, Yee KWL, Geddes M, Leitch HA, Christou G, Banerji V, Leber B, Khalaf D, St-Hilaire E, Finn N, Nevill T, Keating MM, Storring J, Parmentier A, Thambipillai A, Tang D, Westcott C, Cameron C, Spin P. Buckstein R, et al. Among authors: leber b. Leuk Lymphoma. 2023 Mar;64(3):651-661. doi: 10.1080/10428194.2022.2156793. Epub 2023 Jan 6. Leuk Lymphoma. 2023. PMID: 36606533
Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes.
Mozessohn L, Li Q, Liu N, Leber B, Khalaf D, Sabloff M, Christou G, Yee K, Chodirker L, Parmentier A, Siddiqui M, Mamedov A, Zhang L, Liu Y, Earle CC, Cheung MC, Mittmann N, Buckstein R. Mozessohn L, et al. Among authors: leber b. JCO Oncol Pract. 2023 Apr;19(4):e559-e569. doi: 10.1200/OP.22.00668. Epub 2023 Feb 10. JCO Oncol Pract. 2023. PMID: 36763927 Free PMC article.
Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis.
Aghel N, Lui M, Wang V, Khalaf D, Mian H, Hillis C, Walker I, Leber B, Lipton JH, Aljama M, Lepic K, Berg T, Garcia-Horton A, Petropoulos J, Masoom H, Leong DP. Aghel N, et al. Among authors: leber b. Bone Marrow Transplant. 2023 May;58(5):478-490. doi: 10.1038/s41409-023-01928-2. Epub 2023 Feb 27. Bone Marrow Transplant. 2023. PMID: 36849807 Review.
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy.
Khadadah FM, Cerquozzi S, Olney HJ, Fraga C, Dudebout J, Xenocostas A, Finn N, Ethier V, Savoie ML, Busque L, Jamani K, Kuruvilla P, Faught C, Leber B, Kaedbey R, Assouline SE, Kim D. Khadadah FM, et al. Among authors: leber b. Leuk Res. 2023 Oct;133:107374. doi: 10.1016/j.leukres.2023.107374. Epub 2023 Aug 22. Leuk Res. 2023. PMID: 37657146
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Patel PA, Sabloff M, Keating MM, Zhu N, Gabrail NY, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern AE, O'Connell CL, Roboz GJ, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Shastri A, Dao KH, Oganesian A, Hao Y, Keer HN, Azab M, Savona MR. Garcia-Manero G, et al. Among authors: leber b. Lancet Haematol. 2024 Jan;11(1):e15-e26. doi: 10.1016/S2352-3026(23)00338-1. Lancet Haematol. 2024. PMID: 38135371 Clinical Trial.
Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC-ENHANCE.
Buckstein R, Callum J, Prica A, Bowen D, Wells RA, Leber B, Heddle N, Chodirker L, Cheung M, Mozessohn L, Yee K, Gallagher J, Parmentier A, Jamula E, Zhang L, Mamedov A, Stanworth SJ, Lin Y. Buckstein R, et al. Among authors: leber b. Transfusion. 2024 Feb;64(2):223-235. doi: 10.1111/trf.17721. Epub 2024 Feb 7. Transfusion. 2024. PMID: 38323704 Clinical Trial.
Identification of cells of leukemic stem cell origin with non-canonical regenerative properties.
Hollands CG, Boyd AL, Zhao X, Reid JC, Henly C, ElRafie A, Boylan D, Broder E, Kalau O, Johnson P, Mark A, McNicol J, Xenocostas A, Berg T, Foley R, Trus M, Leber B, Garcia-Horton A, Campbell C, Bhatia M. Hollands CG, et al. Among authors: leber b. Cell Rep Med. 2024 Apr 16;5(4):101485. doi: 10.1016/j.xcrm.2024.101485. Epub 2024 Apr 5. Cell Rep Med. 2024. PMID: 38582086 Free PMC article.
Improvement in quality of life in MDS patients who become transfusion independent after treatment.
Wan BA, Alibhai SMH, Chodirker L, Mozessohn L, Geddes M, Zhu N, Trottier AM, St-Hilaire E, Finn N, Leber B, Khalaf D, Christou G, Sabloff M, Leitch HA, Shamy A, Yee KWL, Storring J, Nevill TJ, Houston BL, Elemary M, Delage R, Parmentier A, Siddiqui M, Mamedov A, Zhang L, Buckstein R. Wan BA, et al. Among authors: leber b. Leuk Lymphoma. 2024 Nov 9:1-10. doi: 10.1080/10428194.2024.2422844. Online ahead of print. Leuk Lymphoma. 2024. PMID: 39520728
254 results